Results 1 to 10 of about 771 (95)

A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose

Research in Pharmaceutical Sciences, 2022
Background and purpose: The study was aimed at validating a simple, rapid, and low-cost LC-MS/MS method for carvedilol and 4/-hydroxyphenyl carvedilol assay in human plasma. The validated method was applied to investigate the pharmacokinetics after a low
Wanna Eiamart, Nantaporn Prompila, Yaowatree Jumroen, Nonlanee Sayankuldilok, Pajaree Chariyavilaskul, Supeecha Wittayalertpanya   +5 more
doaj   +1 more source

Comparative Study of Selected Excipients’ Influence on Carvedilol Release from Hypromellose Matrix Tablets

Pharmaceutics, 2023
Solid dosage forms based on hypromellose (HPMC) with prolonged/extended drug release are very important from the research and industrial viewpoint. In the present research, the influence of selected excipients on carvedilol release performance from HPMC ...
Tadej Ojsteršek, Grega Hudovornik, Franc Vrečer   +2 more
doaj   +1 more source

Central composite design for the development of carvedilol-loaded transdermal ethosomal hydrogel for extended and enhanced anti-hypertensive effect

Journal of Nanobiotechnology, 2021
Background Carvedilol, the anti-hypertensive drug, has poor bioavailability when administered orally. Ethosomes-mediated transdermal delivery is considered a potential route of administration to increase the bioavailability of carvedilol.
Padmanabha Rao Amarachinta, Garima Sharma, Noufel Samed, Ananda Kumar Chettupalli, Madhusudhan Alle, Jin-Chul Kim   +5 more
doaj   +1 more source

Mechanism of carvedilol induced action potential and calcium alternans

Channels, 2022
Carvedilol is a nonspecific β-blocker clinically used for the treatment of cardiovascular diseases but has also been shown to have profound effects on excitation-contraction coupling and Ca signaling at the cellular level. We investigate the mechanism by
Elizabeth Martinez-Hernandez, Giedrius Kanaporis, Lothar A. Blatter   +2 more
doaj   +1 more source

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

Scientific Reports, 2023
The pandemic of coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a significant impact on the economy and public health worldwide.
Chunye Zhang, Jiazheng Liu, Yuxiang Sui, Shuai Liu, Ming Yang   +4 more
doaj   +1 more source

Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF ...
Brian Schwartz, Colin Pierce, Christian Madelaire, Morten Schou, Søren Lund Kristensen, Gunnar H. Gislason, Lars Køber, Christian Torp‐Pedersen, Charlotte Andersson   +8 more
doaj   +1 more source

Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems

Pharmaceuticals, 2021
Chitosan is a valued excipient due to its biocompatibility properties and increasing solubility of poorly water-soluble drugs. The research presented in this paper concerns the preparation of binary combinations of chitosan (deacetylated chitin) with ...
Szymon Sip, Magdalena Paczkowska-Walendowska, Natalia Rosiak, Andrzej Miklaszewski, Katarzyna Grabańska-Martyńska, Karolina Samarzewska, Judyta Cielecka-Piontek   +6 more
doaj   +1 more source

Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias

Journal of Cardiovascular Development and Disease, 2022
The study investigates the prognostic role of treatment with carvedilol as compared to metoprolol in patients with ventricular tachyarrhythmias. A large retrospective registry was used including consecutive patients on beta-blocker (BB) treatment with ...
Tobias Schupp, Michael Behnes, Mohammad Abumayyaleh, Kathrin Weidner, Jonas Rusnak, Kambis Mashayekhi, Thomas Bertsch, Ibrahim Akin   +7 more
doaj   +1 more source

COMPARATIVE CONTROLLED STUDY OF ANTIHYPERTENSIVE EFFICACY AND SAFETY OF CARVEDILOL IN PATIENTS WITH HYPERTENSION AND OBESITY OR DIABETES 2 TYPE (BASED ON RESULTS OF MULTICENTER TRIAL ACCORD)

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study efficacy and safety of beta-blocker with vasodilating properties carvedilol (Acridilole, Akrihin, Russia) as a part of the combined therapy of patients with arterial hypertension (HT) and diabetes mellitus 2 type (DM2) and/or obesity ...
Yu. V. Yu.V. Lukina, S. Yu. Martsevich, A. D. Deev, S. A. Shalnova   +3 more
doaj   +3 more sources

Drug delivery of carvedilol (cardiovascular drug) using phosphorene as a drug carrier: a DFT study

Journal of Taibah University for Science, 2022
2D nanomaterial phosphorene is a chemistically stable, biocompatible, and biodegradable drug delivery platform. This study investigates the drug loading efficiency of phosphorene for the cardiovascular drug carvedilol using density-functional theory (DFT)
Javeria Rafique, Qaba Qusain Afzal, Mehvish Perveen, Javed Iqbal, Mohammed Salim Akhter, Sidra Nazir, M. S. Al-Buriahi, Sultan Alomairy, Z. A. Alrowaili   +8 more
doaj   +1 more source